|
시장보고서
상품코드
2127890
액티빈 신호전달 억제제 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Activin Signaling Inhibitors Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
액티빈 신호전달 억제제 시장 성장요인
세계 액티빈 신호전달 억제제 시장은 2025년에 37억 3,000만 달러 규모에 달했으며, 2026년 45억 5,000만 달러에서 2034년에는 118억 달러로 성장하여, 예측 기간 동안 연평균 성장률(CAGR) 11.89%를 기록할 것으로 전망됩니다. 북미는 혁신적인 생물학적 제제의 조기 상용화, 탄탄한 의료 인프라, 희귀질환 치료에 대한 투자 확대에 힘입어 2025년 45.57%의 시장 점유율을 차지하며 세계 시장을 주도했습니다.
액티빈 신호전달 억제제는 비정상적인 액티빈 및 변형 성장 인자-β(TGF-β) 신호전달 경로와 관련된 질환의 치료를 목적으로 하는 유망한 표적형 생물학적 제제로 부상하고 있습니다. 이러한 치료법은 폐동맥 고혈압(PAH), 혈액 질환, 신경근 질환, 비만, 대사성 질환 및 일부 희귀 유전성 질환의 치료에서 큰 주목을 받고 있습니다. 규제 당국의 승인 증가, 임상 파이프라인 확대, 그리고 제약 업계의 적극적인 투자가 세계 시장의 성장을 가속화하고 있습니다.
시장 동향
희귀질환 치료 및 정밀 의학에 대한 관심이 높아지고 있는 것은 액티빈 신호전달 억제제 시장을 견인하는 가장 영향력 있는 동향 중 하나입니다. 제약사들은 치료 선택지가 제한적인 질환을 해결하기 위해 액티빈 및 미오스타틴 경로를 표적으로 하는 단일클론 항체, 리간드 트랩, 수용체 융합 단백질의 개발을 점점 더 적극적으로 추진하고 있습니다.
또 다른 주목할 만한 동향은 비만, 근육량 유지 및 대사성 질환을 대상으로 한 임상 연구의 확대입니다. 일부 생명공학 기업들은 체중 감량 치료 중 제지방 근육량을 유지하기 위한 액티빈 경로 억제제를 연구하고 있으며, 희귀질환을 넘어 새로운 상업적 기회를 개척하고 있습니다.
시장 촉진요인
희귀질환 및 전문 질환의 유병률 증가는 시장의 주요 성장 요인이 되고 있습니다. 폐동맥 고혈압, β-지중해빈혈, 골수이형성증후군, 진행성 골화성 섬유이형성증(FOP), 척수성 근위축증과 같은 질환에는 단순히 증상을 관리하는 것을 넘어, 질병의 진행을 억제할 수 있는 첨단 표적 치료제가 요구되고 있습니다.
또한, 희귀질환 치료제에 대한 규제 당국의 적극적인 지원, 의료비 증가, 바이오의약품 채택 확대, 그리고 혁신적인 의약품 개발에 대한 투자 증대가 시장 확장을 지속적으로 뒷받침하고 있습니다. 아울러, ‘퍼스트-인-클래스(First-in-Class)’ 치료제의 승인 성공도 의료진의 신뢰와 시장 내 수용을 강화하고 있습니다.
시장 제약요인
견조한 성장 전망이 있는 반면, 생물학적 제제의 높은 개발 비용으로 인해 시장은 과제에 직면해 있습니다. 단일클론 항체나 수용체 융합 단백질의 개발에는 장기간에 걸친 임상시험, 첨단 제조 공정, 그리고 막대한 연구 투자가 필요합니다.
게다가 임상시험 중 안전성 문제가 확인될 경우, 승인이 지연되거나 유망한 후보 약물의 개발이 중단될 가능성이 있습니다. 높은 치료비와 보험 급여 제한 또한, 특히 신흥 헬스케어 시장에서 환자들이 치료를 받을 기회를 제한하고 있습니다.
시장 기회
이 시장은 희귀질환 치료제(오르판 의약품)의 개발 및 새로운 적응증 확장을 통해 큰 기회를 제공하고 있습니다. 각 기업은 비만 관리, 근위축성 질환, 심대사성 질환 및 기타 희귀 유전성 질환을 대상으로 한 액티빈 경로 억제제 연구를 적극적으로 추진하고 있습니다.
전문 바이오의약품 분야의 프리미엄 가격 책정 기회, 희귀질환 적응증에 대한 신속한 승인 절차, 그리고 연구 제휴의 확대를 통해 예측 기간 동안 매력적인 장기 성장 전망이 나타날 것으로 예상됩니다.
시장의 과제
주요 과제 중 하나는 상업적으로 승인된 치료법이 제한적이라는 점입니다. 대부분의 액티빈 신호전달 억제제는 여전히 임상 개발 단계에 있으며, 의료진에게 널리 채택되기 위해서는 장기적인 안전성 및 유효성에 대한 추가 데이터 확보가 필요합니다.
또한, 엄격한 규제 당국의 심사, 보험사의 급여 요건, 기존 치료 옵션과의 경쟁이 신속한 상용화의 걸림돌로 남아 있습니다.
세분화 분석
약제 분류별로는, 수용체 융합 기술을 활용한 승인된 치료법의 상업적 성공에 힘입어 2025년에는 ActRII 리간드 트랩 및 융합 단백질이 시장을 독점했습니다. 반면, 미오스타틴/액티빈 경로 억제제의 경우, 여러 질환 분야에서 임상 개발이 확대되고 있어 예측 기간 동안 가장 빠른 성장을 기록할 것으로 예상됩니다.
적응증별로는 2025년에 혈액 질환이 가장 큰 시장 점유율을 차지했습니다. 이는 골수이형성증후군 및 β-지중해빈혈에 따른 빈혈에 대한 액티빈 경로 치료법의 채택이 증가한 데 기인합니다. 반면, 기업들이 비만 및 근기능 유지 요법에 대한 연구를 확대하고 있어, 대사성 질환 및 심대사성 질환이 가장 높은 성장률을 보일 것으로 예상됩니다.
연령대별로는 성인 환자를 대상으로 한 승인된 치료법이 집중되어 있어 성인 부문이 시장을 주도했습니다. 투여 경로별로는 환자의 편의성이 향상되고 장기적인 외래 치료에 적합하기 때문에 피하 주사가 가장 큰 점유율을 차지했습니다. 유통 채널과 관련하여, 고가의 생물학적 제제에 수반되는 전문적인 투여 및 모니터링 요건으로 인해 병원 약국이 계속해서 주요 부문으로 자리매김했습니다.
지역별 전망
북미는 신속한 규제 당국의 승인, 선진적인 바이오의약품 인프라, 그리고 강력한 제약 혁신에 힘입어 2025년에는 17억 달러에 달하며 계속해서 최대 지역 시장이 되었습니다. 미국 시장은 2026년에 19억 1,000만 달러에 달하며, 세계적 리더로서의 위치를 유지할 것으로 예상됩니다.
유럽은 전문 바이오의약품에 대한 접근성 확대와 유리한 규제 체제에 힘입어 2026년에는 12억 4,000만 달러에 달할 것으로 예측되며, 강력한 성장이 기대됩니다. 독일과 영국은 계속해서 이 지역의 주요 기여국이 될 전망입니다.
아시아태평양은 바이오의약품 제조에 대한 투자 확대, 희귀질환에 대한 인식 제고, 그리고 중국, 일본, 인도에서의 의약품 연구 확대에 힘입어 2026년에는 9억 1,000만 달러에 달할 것으로 예상됩니다.
라틴아메리카 및 중동 및 아프리카에서는 의료 인프라 개선과 주요 의료 거점에서의 첨단 생물학적 제제 치료 접근성 확대에 힘입어 꾸준한 성장이 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 액티빈 신호전달 억제제 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.09.11Growth Factors of activin signaling inhibitors Market
The global activin signaling inhibitors market was valued at USD 3.73 billion in 2025 and is expected to grow from USD 4.55 billion in 2026 to USD 11.80 billion by 2034, registering a CAGR of 11.89% during the forecast period. North America dominated the global market with a 45.57% market share in 2025, supported by the early commercialization of innovative biologics, strong healthcare infrastructure, and rising investments in rare disease therapies.
Activin signaling inhibitors are emerging as a promising class of targeted biologic therapies designed to treat disorders associated with abnormal activin and transforming growth factor-beta (TGF-B) signaling pathways. These therapies are gaining significant attention for treating pulmonary arterial hypertension (PAH), hematologic disorders, neuromuscular diseases, obesity, metabolic disorders, and several rare genetic conditions. Increasing regulatory approvals, expanding clinical pipelines, and strong pharmaceutical investments are accelerating market growth worldwide.
Market Trends
The growing focus on rare disease treatment and precision medicine is one of the most influential trends driving the activin signaling inhibitors market. Pharmaceutical companies are increasingly developing monoclonal antibodies, ligand traps, and receptor fusion proteins targeting activin and myostatin pathways to address diseases with limited treatment options.
Another notable trend is the expansion of clinical research into obesity, muscle preservation, and metabolic disorders. Several biotechnology companies are investigating activin pathway inhibitors for preserving lean muscle mass during weight loss therapies, opening new commercial opportunities beyond rare diseases.
Market Drivers
The increasing prevalence of rare and specialty diseases is a major growth driver for the market. Conditions such as pulmonary arterial hypertension, beta-thalassemia, myelodysplastic syndromes, fibrodysplasia ossificans progressiva (FOP), and spinal muscular atrophy require advanced targeted therapies capable of modifying disease progression rather than merely managing symptoms.
Furthermore, favorable regulatory support for orphan drugs, rising healthcare expenditure, growing biologics adoption, and increasing investments in innovative drug development continue to support market expansion. The successful approval of first-in-class therapies has also strengthened physician confidence and commercial acceptance.
Market Restraints
Despite strong growth prospects, the market faces challenges due to the high cost of biologic drug development. Developing monoclonal antibodies and receptor fusion proteins requires lengthy clinical trials, sophisticated manufacturing processes, and significant research investments.
In addition, safety concerns observed during clinical trials may delay approvals or discontinue promising drug candidates. High treatment costs and reimbursement limitations also restrict wider patient access, particularly in emerging healthcare markets.
Market Opportunities
The market offers substantial opportunities through orphan drug development and expansion into new therapeutic indications. Companies are actively exploring activin pathway inhibitors for obesity management, muscle wasting disorders, cardiometabolic diseases, and additional rare genetic disorders.
Premium pricing opportunities for specialty biologics, faster regulatory pathways for orphan indications, and expanding research collaborations are expected to create attractive long-term growth prospects throughout the forecast period.
Market Challenges
One of the major challenges remains the limited number of commercially approved therapies. Most activin signaling inhibitors remain in clinical development, requiring additional long-term safety and efficacy data before achieving widespread physician adoption.
Moreover, stringent regulatory reviews, payer reimbursement requirements, and competition from existing treatment options continue to create barriers to faster commercialization.
Segmentation Analysis
Based on drug class, ActRII ligand traps and fusion proteins dominated the market in 2025 due to the commercial success of approved therapies utilizing receptor-fusion technology. Meanwhile, myostatin/activin pathway inhibitors are projected to record the fastest growth during the forecast period as clinical development expands across multiple disease areas.
By indication, hematologic disorders accounted for the largest market share in 2025, supported by the increasing adoption of activin pathway therapies for anemia associated with myelodysplastic syndromes and beta-thalassemia. Meanwhile, metabolic and cardiometabolic disorders are expected to witness the highest growth as companies expand research into obesity and muscle preservation therapies.
Based on age group, the adult segment dominated the market due to the concentration of approved therapies targeting adult patients. By route of administration, subcutaneous injections held the largest share because of improved patient convenience and suitability for long-term outpatient treatment. In terms of distribution channels, hospital pharmacies remained the leading segment owing to the specialist administration and monitoring requirements associated with high-cost biologic therapies.
Regional Outlook
North America remained the largest regional market, reaching USD 1.70 billion in 2025, driven by rapid regulatory approvals, advanced biologics infrastructure, and strong pharmaceutical innovation. The U.S. market is expected to reach USD 1.91 billion in 2026, maintaining its leadership position globally.
Europe is projected to experience strong growth, reaching USD 1.24 billion in 2026, supported by expanding access to specialty biologics and favorable regulatory frameworks. Germany and the U.K. continue to be major regional contributors.
Asia Pacific is expected to reach USD 0.91 billion in 2026, driven by increasing investments in biologics manufacturing, rare disease awareness, and expanding pharmaceutical research across China, Japan, and India.
Latin America together with the Middle East & Africa are anticipated to witness steady growth as healthcare infrastructure improves and access to advanced biologic therapies expands across major healthcare centers.
Competitive Landscape
The activin signaling inhibitors market remains semi-consolidated, with leading pharmaceutical companies investing heavily in clinical development, regulatory approvals, acquisitions, and strategic partnerships. Major companies include Bristol Myers Squibb Company, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Keros Therapeutics, Takeda Pharmaceutical Company Limited, Scholar Rock Holding Corporation, Biohaven Ltd., Eli Lilly and Company, GSK plc, and Laekna, Inc.
Recent product approvals, expanding Phase II and Phase III clinical programs, and ongoing innovation in targeted biologics are strengthening competitive positioning while creating new commercial opportunities across multiple therapeutic areas.
Conclusion
The global activin signaling inhibitors market is positioned for robust expansion as targeted biologic therapies become increasingly important in treating rare diseases, hematologic disorders, pulmonary arterial hypertension, metabolic disorders, and neuromuscular conditions. Valued at USD 3.73 billion in 2025, the market is forecast to grow to USD 4.55 billion in 2026 and reach USD 11.80 billion by 2034, reflecting strong long-term demand. Continued regulatory approvals, expanding clinical pipelines, advances in biologics research, and growing investment in precision medicine are expected to drive sustained market growth throughout the forecast period.
Segmentation By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Region
By Drug Class * ActRII Ligand Traps/Fusion Proteins
- Activin Receptor-Targeting Monoclonal Antibodies
- Myostatin/Activin Pathway Inhibitors
- Other Activin-Signaling Modulators
By Indication * Hematologic Disorders
- Cardiopulmonary Disorders
- Muscle/Neuromuscular Disorders
- Metabolic/Cardiometabolic disorders
- Others
By Age Group * Pediatric
- Adults
By Route of Administration * Subcutaneous
- Intravenous
- Others
By Distribution Channel * Hospital Pharmacies
- Specialty Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region * North America (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 3.5. Market Challenges
4. Key Insights
- 4.1. Prevalence of Key Disease Indications, By Key Regions/Countries
- 4.2. Pipeline Analysis, By Key Regions
- 4.3. New Product Launches, By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. Regulatory & Reimbursement Scenario, By Key Countries
5. Global Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. ActRII Ligand Traps/Fusion Proteins
- 5.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 5.1.3. Myostatin/Activin Pathway Inhibitors
- 5.1.4. Other Activin-Signaling Modulators
- 5.2. Market Analysis, Insights and Forecast - By Indication
- 5.2.1. Hematologic Disorders
- 5.2.2. Cardiopulmonary Disorders
- 5.2.3. Muscle/Neuromuscular Disorders
- 5.2.4. Metabolic/Cardiometabolic disorders
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Subcutaneous
- 5.4.2. Intravenous
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Specialty Pharmacies
- 5.5.3. Drug Stores & Retail Pharmacies
- 5.5.4. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast - Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. ActRII Ligand Traps/Fusion Proteins
- 6.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 6.1.3. Myostatin/Activin Pathway Inhibitors
- 6.1.4. Other Activin-Signaling Modulators
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1. Hematologic Disorders
- 6.2.2. Cardiopulmonary Disorders
- 6.2.3. Muscle/Neuromuscular Disorders
- 6.2.4. Metabolic/Cardiometabolic disorders
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Route of Administration
- 6.4.1. Subcutaneous
- 6.4.2. Intravenous
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Specialty Pharmacies
- 6.5.3. Drug Stores & Retail Pharmacies
- 6.5.4. Online Pharmacies
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. ActRII Ligand Traps/Fusion Proteins
- 7.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 7.1.3. Myostatin/Activin Pathway Inhibitors
- 7.1.4. Other Activin-Signaling Modulators
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1. Hematologic Disorders
- 7.2.2. Cardiopulmonary Disorders
- 7.2.3. Muscle/Neuromuscular Disorders
- 7.2.4. Metabolic/Cardiometabolic disorders
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Route of Administration
- 7.4.1. Subcutaneous
- 7.4.2. Intravenous
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Specialty Pharmacies
- 7.5.3. Drug Stores & Retail Pharmacies
- 7.5.4. Online Pharmacies
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. ActRII Ligand Traps/Fusion Proteins
- 8.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 8.1.3. Myostatin/Activin Pathway Inhibitors
- 8.1.4. Other Activin-Signaling Modulators
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1. Hematologic Disorders
- 8.2.2. Cardiopulmonary Disorders
- 8.2.3. Muscle/Neuromuscular Disorders
- 8.2.4. Metabolic/Cardiometabolic disorders
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Route of Administration
- 8.4.1. Subcutaneous
- 8.4.2. Intravenous
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Specialty Pharmacies
- 8.5.3. Drug Stores & Retail Pharmacies
- 8.5.4. Online Pharmacies
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. Southeast Asia
- 8.6.5. Australia
- 8.6.6. Rest of Asia Pacific
9. Latin America Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. ActRII Ligand Traps/Fusion Proteins
- 9.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 9.1.3. Myostatin/Activin Pathway Inhibitors
- 9.1.4. Other Activin-Signaling Modulators
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1. Hematologic Disorders
- 9.2.2. Cardiopulmonary Disorders
- 9.2.3. Muscle/Neuromuscular Disorders
- 9.2.4. Metabolic/Cardiometabolic disorders
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Route of Administration
- 9.4.1. Subcutaneous
- 9.4.2. Intravenous
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Specialty Pharmacies
- 9.5.3. Drug Stores & Retail Pharmacies
- 9.5.4. Online Pharmacies
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Activin Signaling Inhibitors Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. ActRII Ligand Traps/Fusion Proteins
- 10.1.2. Activin Receptor-Targeting Monoclonal Antibodies
- 10.1.3. Myostatin/Activin Pathway Inhibitors
- 10.1.4. Other Activin-Signaling Modulators
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1. Hematologic Disorders
- 10.2.2. Cardiopulmonary Disorders
- 10.2.3. Muscle/Neuromuscular Disorders
- 10.2.4. Metabolic/Cardiometabolic disorders
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Age Group
- 10.3.1. Pediatric
- 10.3.2. Adults
- 10.4. Market Analysis, Insights and Forecast - By Route of Administration
- 10.4.1. Subcutaneous
- 10.4.2. Intravenous
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Specialty Pharmacies
- 10.5.3. Drug Stores & Retail Pharmacies
- 10.5.4. Online Pharmacies
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Bristol Myers Squibb Company
- 11.2.2. Merck & Co., Inc.
- 11.2.3. Regeneron Pharmaceuticals, Inc.
- 11.2.4. Keros Therapeutics, Inc.
- 11.2.5. Takeda Pharmaceutical Company Limited
- 11.2.6. Scholar Rock Holding Corporation
- 11.2.7. Biohaven Ltd.
- 11.2.8. Eli Lilly and Company
- 11.2.9. GSK plc
- 11.2.10. Laekna, Inc.
